IWIlse Wegner

Ilse Wegner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ilse Wegner has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Begeleiding van vrouwen met epilepsie en een kinderwens

    by Inge Brummelhuis, Ilse Wegner

    De begeleiding en behandeling van vrouwen met epilepsie rondom de zwangerschap vraagt om maatwerk. Hierbij is het balanceren tussen enerzijds zo min mogelijk blootstelling van de foetus aan anti-aanvalsmedicatie en anderzijds het risico op aanvallen bij de moeder beperken. Het zorgpad ‘Zwangerschap & Epilepsie’ levert dit maatwerk vóór, tijdens en na de zwangerschap.

  • Open Access

    Levetiracetam en zwangerschap: relatie tussen concentraties en aanvallen

    by Meike Schelhaas, Ilse Wegner, Mireille Edens, Elisabeth Wammes-Van der Heijden, Daniel Touw, Peter Ter Horst

    Optimale behandeling van epilepsie tijdens de zwangerschap is belangrijk voor zowel moeder als kind. De dosering van anti-aanvalsmedicatie moet soms worden aangepast vanwege een snellere eliminatie dan gebruikelijk. In een uitgebreide studie werd de daling van serumconcentraties van levetiracetam en de consequenties hiervan voor de aanvalsfrequentie onderzocht.

  • Lactation studies of anticonvulsants: a quality review

    by Douwe H. van der Meer, Andre Wieringa, Ilse Wegner, Bob Wilffert, Peter G. J. ter Horst

    Aim: The aim of this review was to investigate the quality of the current literature on the transfer of anticonvulsants to breast milk to provide an overview of which anticonvulsants are in need of further research.Methods: We reviewed the quality of the available lactation studies for 19 anticonvulsants against the guidelines of theFood andDrugAdministration (FDA) and theInternationalLactationConsultantAssociation (ILCA).Results: Except for one study on lamotrigine and one case report on gabapentin, no study on anticonvulsants had both the absolute infant dose (AID) and milk to plasma ratio (M : P) correctly assessed. Only one study on carbamazepine, phenytoin and vigabatrin was found that correctly assessed theAID. The main cause for this low number is the lack of essential details in published studies, since 25 of 62 studies were case reports, letters or abstracts. Other major shortcomings were the lack of information on sampling methods, the number of samples in a particular dose interval as well as the low number of study participants.Conclusion: The quality of the current literature on the transfer of anticonvulsants to breast milk is low, except for lamotrigine, which makes it hard to draw conclusions about the safety of the use of anticonvulsants during the lactation period. Therefore, further research is needed.


  • Effect of oral contraceptives on lamotrigine levels depends on comedication

    by I. Wegner, A. J. Wilhelm, D. A. J. E. Lambrechts, J. W. Sander, D. Lindhout

    Objectives To evaluate prospectively the influence of cyclic oral contraceptive (OC) use on lamotrigine (LTG) serum levels when used in combination therapy. Methods Women with epilepsy using LTG in combination with valproate (VPA; n=7), carbamazepine (CBZ; n=3) or oxcarbazepine (OXC; n=1) were evaluated during two periods of 28days cyclic OC use, monitoring antiepileptic drug (AED) levels every other day with the dried blood spot sampling method. Results were compared with women on LTG monotherapy and OCs (n=12). Pharmacokinetic analysis was performed using NONMEM software. Results Mean study population value of LTG clearance estimated by the final model was 3.17l/h. Introduction of covariates for comedication (VPA, CBZ, OXC and OC) significantly reduced the between-subject variability. A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02 +/- 0.38l/h, OC-free week 3.03 +/- 0.39l/h) and in LTG-CBZ combination (clearance with OC 4.95 +/- 0.15l/h, OC-free week 4.15 +/- 0.26l/h). No influence of OC was found in LTG-VPA combination (clearance with OC 0.99 +/- 0.16l/h, OC-free week 0.90 +/- 0.15l/h). Conclusions Adding OCs to LTG monotherapy or the combination LTG-CBZ significantly increased the LTG clearance and thus reduced LTG serum levels. In the combination LTG-CBZ, OCs had a non-significant effect on CBZ clearance. No significant influence of cyclic OC use on LTG or VPA clearance was found when these AEDs were used in combination.


  • The impact of age on lamotrigine and oxcarbazepine kinetics: A historical cohort study

    by Ilse Wegner, Abraham J. Wilhelm, Josemir W. Sander, Dick Lindhout


  • Open Access

    Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy

    by Ilse Wegner, Peter Edelbroek, Gerrit‐Jan De Haan, Dick Lindhout, Josemir W. Sander

    Little is known about pregnancy‐induced alterations in the pharmacokinetics of the newer antiepileptic drugs, especially when used in combinations. Two women receiving combination therapy of lamotrigine (LTG) and oxcarbazepine (OXC) were followed prospectively during pregnancy and puerperium. Steady‐state concentrations of LTG and the active metabolite of OXC, 10‐hydroxycarbazepine (MHD), were measured at regular intervals using a dried blood spot method, and clearances were calculated. A strong effect of pregnancy on the clearance of both LTG and MHD was seen. An increase in seizure frequency occurred in both women. This stresses the importance of therapeutic drug monitoring of LTG and MHD during pregnancy. In case of breakthrough seizures or increased seizure frequency, dosage adjustment of both drugs may be required.


  • Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives

    by Ilse Wegner, Peter M. Edelbroek, Saskia Bulk, Dick Lindhout

    Objective: We prospectively evaluated the fluctuation of lamotrigine (LTG) clearance during the menstrual cycle. We also assessed the effect of postmenopausal status and investigated in detail the effect of oral contraceptives (OCs) on LTG clearance. Methods: Three groups of women with epilepsy using LTG monotherapy were evaluated. Women in the first group (n = 7) had a regular cycle and did not use OCs; the second group used a 1-phase combined OC (n = 7), and the third group (n = 7) was postmenopausal. Two menstrual cycles or at least 2 months (postmenopausal women) were assessed, monitoring LTG levels every other day. Results: The mean apparent LTG clearance in women of reproductive age not using OCs was 49 (SD 22.6, range 20.4–83.5) L/24 hours. No significant effect of endogenous hormones on LTG clearance was found. In women using OCs, the mean LTG clearance was 126 (SD 60.2, range 44.3–205) L/24 hours. There was an increase in LTG levels during the pill-free week, with maximum levels 54% (range 29%–129%) higher than baseline levels. LTG levels decreased to the baseline value within a mean of 8 days of starting OC use (SD 3.7, range 2.5–16.5). In the postmenopausal women, the mean clearance was 82 (SD 38.4, range 35.9–125) L/24 hours. Conclusions: We observed a higher mean lamotrigine (LTG) clearance in postmenopausal women compared with young women not using oral contraceptives (OCs) and confirmed that OC use may have a strong effect on LTG clearance. There was no significant fluctuation of LTG clearance during the menstrual cycle.